The genetic and pharmacologic inhibition of Drp1 reduced the migratory ability of oncocytic thyroid cancer cells, suggesting that Drp1 plays a role beyond mitochondrial morphology—this may directly impact metastatic capacity. Here, DNM1L is linked to thyroid cancer.